ArticleCancers2022

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies.

Jason C Andrechak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.